India Glycols Ltd Q1 FY26 Concall Decoded – Spirits, Biofuels & Bunty Bubli Hangover

1. Opening Hook

The quarter felt like India Glycols was running both a distillery and an energy ministry—one hand pouring whisky shots, the other blending ethanol into petrol tanks. Imagine Bunty Bubli (their liquor mascot) doing a cameo in a Fast & Furious movie, yelling “20% ethanol blending, baby!” as Vin Diesel revs up. Numbers were spirited, literally. And yet, chemicals sulked in a corner like a rejected fresher at the party. Stick around—because between country liquor dominance, biofuel tailwinds, and pharma struggles, this call had more plot twists than a Rohit Shetty cop universe.

2. At a Glance

• Revenue up 7% – Sales grew, CFO claims no “daru accounting,” just real business.
• EBITDA up 18% – Party’s going strong, margins even brought snacks.
• PAT up 21% – Bottom line boozed up nicely, despite debt hangover.
• Margins +128 bps – Efficiency hacks finally paid rent.
• Biofuel revenue +45% – Petrol pump becoming their new bar counter.
• Potable Spirits revenue +22% – Bunty Bubli still the undisputed desi king.
• Ennature Biopharma weak – Pharma cousins are still on life support.
• JV profit +74% – Clariant JV went from “meh” to “wow” in a year.

3. Management’s Key Commentary

CEO Rupark Sarswat: “We had a strong quarter with net revenue up 7%, EBITDA up 18%, PAT up 21%.”
(Translation: We actually made money this time, not just promises in investor PPTs.)

On Spirits: “Bunty Bubli continues to be India’s highest-selling liquor brand.”
(Translation: Forget Radico, Pernod, Diageo—our Bunty still owns UP the way Gabbar owned Ramgarh.)

On Biofuels: “Government’s ethanol blending plan is robust. We hit 19% in FY25, expect 20% in FY26.”
(Translation: Modi ji’s ethanol dream is our cash cow. Cheers to petrol tanks running on sugarcane juice.)

On Chemicals: “Performance Chemicals pipeline looks strong with new capacity expansions.”
(Translation: For once, our chemicals aren’t just crying in the corner about Reliance beating us on pricing.)

On JV with Clariant: “Profits jumped 74% YoY, EO price gap with Reliance has normalized.”
(Translation: Earlier Reliance was making us look like street chaiwalas. Now, finally, we can afford Starbucks.)

On Ennature Biopharma: “Margins under pressure due to weak demand and competition.”
(Translation: Pharma segment is like that cousin who keeps failing CA exams. Hopeful, but always disappointing.)

On Capex: “No major capex this year, only maintenance of ~₹40–50 cr.”
(Translation: Wallet zipped. No more drunken spending till the demerger clears.)

4. Numbers Decoded